Organization
National Cancer Center, Goyang-Si, Gyeonggi-Do, South Korea
1 abstract
Abstract
FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.Org: National Cancer Center, Goyang-Si, Gyeonggi-Do, South Korea, CanariaBio, Inc, Lexington, MA, CanariaBio, Inc, Singapore, Severance Hospital, Yonsei University Health System, Seoul, South Korea, John Muir Health, Walnut Creek, CA,